Book a Meeting

Non-Fucosylated Anti-Human JAML (DW55) Therapeutic Antibody (CAT#: BioBet-558ZP) Datasheet

Target
JAML
Isotype
IgG2b,K
Description
ADCC-Enhanced anti-JAML (DW55) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Inflammation
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced JAML antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
AMICA1
Full Name
adhesion molecule, interacts with CXADR antigen 1
Alternative Names
AMICA1; adhesion molecule, interacts with CXADR antigen 1; JAML; AMICA; Gm638; CREA7-1; CREA7-4; junctional adhesion molecule-like; adhesion molecule AMICA; dendritic-cell specific protein CREA7-1; dendritic-cell specific protein CREA7-4; adhesion molecule interacting with CXADR antigen 1
Gene ID
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with JAML include Febrile Seizures, Familial, 5.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and Response to elevated platelet cytosolic Ca2+.
Function
A transmembrane protein of the plasma membrane of leukocytes, which controls the migration and activation of leukocytes by interacting with CXADR, which is a plasma membrane receptor found on neighboring epithelial cells and endothelial cells. The interaction between these two receptors mediates the activation of gamma-delta T cells, which are a subset of T cells in epithelial cells, and are involved in tissue homeostasis and repair. Through epithelial cell cxadr binding, JAML induces downstream cell signaling events in delta T cells through pi3-kinase and MAP kinase. It leads to the proliferation of T cells and the production of cytokines and growth factors, which in turn stimulates epithelial tissue repair. It also controls the migration of leukocytes in epithelial and endothelial tissues through adhesion interaction with epithelial and endothelial CXADR.
Post-translational modifications
1.Glycosylation at Asn76 and Asn231 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2b,K
Antibody Clone
DW55
Host
Human
Species Reactivity
Human
Description
The antibody that specifically bind JAM-like protein (JAML) are useful in a variety of settings such as diagnostic screening, bioassays, and therapeutic intervention for diseases or conditions that are associated with JAML and/or CAR such as inflammation, cancer, scarring, wound healing, respiratory diseases, and other disorders related to epithelial inflammation.
Indication
Inflammation

Inflammation

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.